海鷗股份(603269.SH):2名董監高尚未實施減持
格隆匯11月8日丨海鷗股份(603269.SH)公佈,公司監事會主席劉志正在本次減持計劃實施前持有公司股份164.45萬股,佔公司股份總數的1.7979%;董事、董事會祕書、財務總監劉立在本次減持計劃實施前持有公司股份75.16萬股,佔公司股份總數的0.8217%。上述股份全部來源於海鷗股份首次公開發行股票前已持有的股份,該部分股份已於2019年5月17日解除限售並上市流通。
公司於2019年7月20日披露了《江蘇海鷗冷卻塔股份有限公司部分董監高減持股份計劃公告》。截至2019年11月7日,劉志正、劉立未減持其持有的公司股份,本次減持計劃尚未實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.